A comprehensive approach is necessary for navigating the highly heterogeneous nature of leukemia across different age ...
AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, survival rates are variable after the most important curative approach, intensive ...
An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that suppress their growth ...
Relapsed acute myeloid leukemia (AML) is when cancer returns after a period of remission. Refractory AML means cancer has not responded to multiple rounds of treatment. Both can affect your treatment ...
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results